Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

Stephen Lash, PharmD

Articles by Stephen Lash, PharmD

Costs Associated With Second-Line Therapies for Lung Cancer

ByStephen Lash, PharmD,April Teitelbaum, MD,Henry J. Henk, PhD,Carolina M. Reyes, PhD,Lucinda Benn, MBA

February 2nd 2011

Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.

Latest Updated Articles

Costs Associated With Second-Line Therapies for Lung Cancer
Published: February 2nd 2011 | Updated:

Trending on Pharmacy Times

Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate

Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk

© 2025 MJH Life Sciences^®

All rights reserved.